Juan Jose Lasarte
Overview
Explore the profile of Juan Jose Lasarte including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
86
Citations
2579
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bernasconi-Bisio F, Molina E, Ibarra V, Ibanez-Sala I, Rochira F, Jauregui P, et al.
Mol Ther Oncol
. 2025 Mar;
33(1):200949.
PMID: 40084273
Chimeric antigen receptor T cell (CAR-T) therapies have revolutionized cancer immunotherapy. Traditional single-chain variable fragments (ScFvs) used as CAR recognition moieties face challenges such as high tonic signaling, compromised binding...
2.
Martin-Otal C, Sanchez-Moreno I, Gomez-Moron A, Castro C, Casares N, Navarro F, et al.
J Immunother Cancer
. 2025 Feb;
13(2).
PMID: 39988346
Background: Phosphatidylserine (PS) exposed on apoptotic cells promotes immune clearance of dead cells without inducing inflammation. Conversely, PS exposure on live tumor cells promotes an immunosuppressive tumor microenvironment that hinders...
3.
Garcia-Lacarte M, Grijalba S, Melchor Sanchez J, Pascual M, Goni E, Clemente-Larramendi I, et al.
Blood
. 2025 Feb;
PMID: 39899878
The contribution of IL-10 secreted by tumoral B cells to the progression and shaping of the microenvironment in diffuse large B-cell lymphoma (DLBCL) with activated B-cell (ABC) phenotype is not...
4.
Ines S, Celia M, Lasarte J, Teresa L
Methods Cell Biol
. 2025 Jan;
191():59-77.
PMID: 39824564
No abstract available.
5.
Serrano A, Zalba S, Lasarte J, Troconiz I, Riva N, Garrido M
Pharmaceutics
. 2024 Nov;
16(11).
PMID: 39598584
The failure of immunotherapies in cancer patients is being widely studied due to the complexities present in the tumor microenvironment (TME), where regulatory T cells (Treg) appear to actively participate...
6.
Silva-Pilipich N, Beloki U, Apaolaza P, Igea A, Salaberry L, Prats-Mari L, et al.
Mol Ther
. 2024 Nov;
33(1):297-316.
PMID: 39563030
Immunostimulatory cytokines and immune checkpoint inhibitors hold promise as cancer therapeutics; however, their use is often limited by reduced efficacy and significant toxicity. In this study, we developed small-format immunocytokines...
7.
Staudt S, Nikolka F, Perl M, Franz J, Leblay N, Leblay N, et al.
bioRxiv
. 2024 Sep;
PMID: 39314273
The microbiome is a complex host factor and key determinant of the outcome of antibody-based and cellular immunotherapy. Its postbiotics are a blend of soluble commensal byproducts that are released...
8.
Palacios-Berraquero M, Rodriguez-Marquez P, Calleja-Cervantes M, Berastegui N, Zabaleta A, Burgos L, et al.
Blood Adv
. 2024 Jul;
8(21):5479-5492.
PMID: 39058976
Hematologic toxicity is a common side effect of chimeric antigen receptor T-cell (CAR-T) therapies, being particularly severe among patients with relapsed or refractory multiple myeloma (MM). In this study, we...
9.
Sanchez-Moreno I, Lasarte-Cia A, Martin-Otal C, Casares N, Navarro F, Gorraiz M, et al.
J Immunother Cancer
. 2024 Jul;
12(7).
PMID: 38955421
Background: Adoptive cell therapy using genetically modified T cells to express chimeric antigen receptors (CAR-T) has shown encouraging results, particularly in certain blood cancers. Nevertheless, over 40% of B cell...
10.
Silva-Pilipich N, Lasarte-Cia A, Lasarte J, Smerdou C
Mol Ther Nucleic Acids
. 2024 Jan;
35(1):102110.
PMID: 38274365
No abstract available.